Elkashef Ahmed, Vocci Frank, Huestis Marilyn, Haney Margaret, Budney Alan, Gruber Amanda, el-Guebaly Nady
Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA.
Subst Abus. 2008;29(3):17-29. doi: 10.1080/08897070802218166.
Marijuana is the number one illicit drug of abuse worldwide and a major public health problem, especially in the younger population. The objective of this article is to update and review the state of the science and treatments available for marijuana dependence based on a pre-meeting workshop that was presented at ISAM 2006. At the workshop, several papers were presented addressing the neurobiology and pharmacology of marijuana and treatment approaches, both psychotherapy and medications, for marijuana withdrawal. Medicolegal and ethical issues concerning marijuana medical use were also discussed. Concise summaries of these presentations are incorporated in this article, which is meant to be an updated review of the state of the science. Major advances have been made in understanding the underpinning of marijuana dependence and the role of the CNS cannabinoid system, which is a major area for targeting medications to treat marijuana withdrawal and dependence, as well as other addictions. Behavioral therapies are efficacious for facilitating abstinence from marijuana. Nefazadone, Marinol, and buspirone are showing early positive signals for efficacy in ameliorating marijuana withdrawal symptoms. Effective psychotherapeutic approaches are available and promising medications studies need to be confirmed in outpatient trials. The next few years looking promising for translational research efforts to make treatment widely accessible to patients with marijuana dependence.
大麻是全球头号滥用非法药物,也是一个主要的公共卫生问题,在年轻人群体中尤为突出。本文的目的是根据在2006年国际成瘾医学学会(ISAM)上举办的会前研讨会,更新并综述大麻依赖的科学现状及可用治疗方法。在研讨会上,有多篇论文发表,涉及大麻的神经生物学和药理学以及大麻戒断的治疗方法,包括心理治疗和药物治疗。还讨论了与大麻医疗使用相关的法医学和伦理问题。本文纳入了这些报告的简要总结,旨在对科学现状进行更新综述。在理解大麻依赖的基础以及中枢神经系统大麻素系统的作用方面已取得重大进展,该系统是开发治疗大麻戒断和依赖以及其他成瘾药物的主要靶点。行为疗法对促进大麻戒断有效。奈法唑酮、屈大麻酚和丁螺环酮在改善大麻戒断症状方面显示出早期积极的疗效信号。有效的心理治疗方法是可用的,且有前景的药物研究需要在门诊试验中得到证实。未来几年,转化研究有望使大麻依赖患者广泛获得治疗。